Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month, the regulator had rejected the drug, Kisunla, ...

The drug had already failed in two phase 3 trials in 2012 – but Lilly pressed on with a third trial in mild Alzheimer’s after spotting a trend in the data suggesting an effect in a small group ...

The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Lilly’s neurodegeneration portfolio is anchored by the Alzheimer’s drug Kisunla, which received FDA approval last July. That antibody drug was internally discovered and developed within Lilly.

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

A new study has found that a common class of medications could dramatically decrease the risk of developing the neurodegenerative disorder.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...